Compare Source Natural with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
INR 74 Cr (Micro Cap)
21.00
37
0.00%
0.22
13.59%
2.87
Total Returns (Price + Dividend) 
Source Natural for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Source Natural Foods & Herbal Supplements Ltd Upgraded to Sell on Technical Improvements
Source Natural Foods & Herbal Supplements Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite ongoing fundamental challenges. The change, effective from 15 Sep 2026, is driven primarily by improvements in technical indicators, while valuation and financial trends present a mixed picture for investors in this pharmaceuticals and biotechnology micro-cap.
Read full news article
Source Natural Foods & Herbal Supplements Ltd Downgraded to Strong Sell Amid Technical Weakness
Source Natural Foods & Herbal Supplements Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 September 2026, reflecting deteriorating technical indicators and underwhelming fundamental performance. Despite some positive quarterly financial results, the company’s long-term outlook remains challenged by weak growth trends and bearish market signals.
Read full news article
Source Natural Foods & Herbal Supplements Ltd Upgraded to Sell on Technical Improvements
Source Natural Foods & Herbal Supplements Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite persistent fundamental challenges. The change, effective from 18 August 2026, is driven primarily by improvements in technical indicators, while valuation and financial trends present a mixed picture for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
10-Sep-2026 | Source : BSENewspaper Publication for the 31st Annual General Meeting of the Company
Notice Of 31St Annual General Meeting
08-Sep-2026 | Source : BSENotice of 31st Annual General Meeting
Reg. 34 (1) Annual Report.
08-Sep-2026 | Source : BSENotice of 31st AGM and Annual report for the financial year 2025-26.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Sriveda Sattva Private Limited (74.37%)
Guttikonda Vara Lakshmi (2.96%)
19.61%
Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is 1.85% vs 3.60% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is -40.32% vs 51.22% in Mar 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 57.79% vs 47.63% in Sep 2024
Growth in half year ended Sep 2025 is 5.56% vs 173.91% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 71.00% vs 40.99% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -5.70% vs 60.56% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 56.68% vs 64.54% in Mar 2025
YoY Growth in year ended Mar 2026 is 17.24% vs 66.67% in Mar 2025






